CHRW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CH Robinson Worldwide (CHRW) is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has supportive analyst sentiment and solid Q1 EPS/net income growth, but the current technical setup is mixed, there is no positive Intellectia signal, insiders are selling, congress trading shows net selling, and the recent price is already near the middle of its short-term range without a clear breakout. For an impatient buyer who does not want to wait for an ideal entry, this still does not look like the best immediate long-term purchase. I would hold off and wait for a better entry rather than buy aggressively now.
CHRW is trading at 171.68, slightly above the prior close, but the broader setup is not strongly bullish. MACD histogram is -1.716 and below zero, though the negative momentum is contracting, which suggests selling pressure is easing rather than reversing strongly. RSI_6 at 42.97 is neutral-to-weak, showing no oversold buy signal. Moving averages are converging, which usually points to a range-bound or transition phase instead of a decisive uptrend. Price is below pivot resistance at 175.53, with support at 163.68 and deeper support at 156.36. Near term, the stock may drift sideways unless it clears 175.53 convincingly.
["Multiple analysts raised price targets after Q1 results, with Baird, Evercore ISI, JPMorgan, Stifel, Raymond James, Citi, Barclays, and Susquehanna turning more constructive or maintaining positive views.", "Q1 earnings improved despite slightly lower revenue: net income rose 8.82% YoY and EPS rose 9.91% YoY.", "Barclays noted efficiency initiatives and AI capabilities helping offset brokerage margin pressure.", "Raymond James described the setup as compelling risk/reward after earnings."]
["No news in the recent week, so there is no fresh event-driven catalyst pushing the stock higher.", "Revenue fell 0.84% YoY in Q1 and gross margin fell 1.02%, showing top-line and margin pressure.", "Insiders are selling, and the selling amount increased 1551.76% over the last month.", "Congress trading data shows 1 sale and 0 purchases in the last 90 days, indicating cautious sentiment from lawmakers.", "No AI Stock Picker or SwingMax signal is present today.", "Technical indicators are not in a strong breakout pattern, with MACD below zero and RSI neutral."]
In 2026 Q1, CHRW showed mixed but improving profitability. Revenue declined slightly to $4.01B, down 0.84% YoY, indicating modest top-line softness. However, net income increased 8.82% YoY to $147.2M and EPS rose 9.91% YoY to $1.22, which is a positive sign of better operating efficiency. Gross margin fell to 16.46%, down 1.02% YoY, so margin pressure remains present even as earnings improved. For a long-term investor, the latest quarter is acceptable but not strong enough to justify an aggressive buy on fundamentals alone.
Analyst sentiment is clearly improving. Over the last two weeks, several firms raised price targets: Baird to $230, Evercore ISI to $222, JPMorgan to $196, Stifel to $207, Raymond James to $210, Citi to $199, Barclays to $210, and Susquehanna to $215. Most firms kept Outperform/Overweight/Buy-style ratings, while TD Cowen and Citi stayed more neutral. Wall Street pros are broadly constructive on CHRW because of better-than-expected Q1 results, margin resilience, and AI-driven efficiency gains. The main con view is that core brokerage margins could still face pressure and demand recovery remains limited, which is why some firms remain Hold/Neutral.
